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ABSTRACT 
 
Background: Protective immune responses induced in the majority of people infected 
with Mycobacterium tuberculosis enable them to control TB infection. Objective: The 
aim of this study was to investigate CD56 and CD16 positive peripheral blood mononu-
clear cells (PBMCs) and leukocyte subsets from multi-drug resistant pulmonary tuber-
culosis (MDR-TB), and compare them with nonresistant (NR) TB patients and healthy 
controls. Methods: 13 MDR-tuberculosis patients, 20 NR-TB individuals and 40 
healthy subjects were included. Peripheral blood mononuclear cells were double stained 
with fluorochrome conjugated antibodies against CD56 and CD16 cell surface markers. 
The phenotype of positive cells was then analyzed by flow cytometry and the percent-
ages of CD56+ CD16+, CD56- CD16+, CD56dimCD16+/-, and CD56brightCD16+/- subsets 
were calculated. Results: There was a significant decline in the percentage of 
CD56+CD16+ lymphocytes in both MDR and NR-TB patients compared with healthy 
controls. We also observed lower proportions of CD56dim/brightCD16+ in addition to 
higher percentages of CD56dim/brightCD16- subsets in all TB patients (p≤0.05). In MDR-
TB, our findings demonstrated a distinct phenotypic feature with increased levels of 
CD56brightCD16- in comparison with both NR-TB and healthy subjects. Conclusion: 
Considering the function of CD56/CD16 expressing cells in TB, we suggest that pheno-
typic characteristics of PBMCs in MDR-TB may correlate with their status of drug re-
sistance and probably with their high mortality rates.  
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INTRODUCTION  
 
M. tuberculosis is responsible for about 2-3 million deaths worldwide (1). Multidrug 
resistant (MDR) strains of M. tuberculosis especially in HIV infected patients are a 
growing problem in many countries (2). It is estimated that one third of the world popu-
lation is infected by M. tuberculosis, but about 90% of the infected subjects never de 
velop the active disease indicating the ability of human immune responses to control the  
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infection (3). Active tuberculosis is associated with prolonged suppression of M. tuber-
culosis specific immune responses and expansion of regulatory T cells leading to de-
creased T cell IFN-γ production (4). The causative agent survives and proliferates 
within macrophages. These cells can be activated by cytokines such as IFN-γ secreted 
by NK and T cells which kill the bacteria. The inflammatory environment induced in 
TB infection recruits other innate effector cells such as NK, macrophages and neutro-
phils leading to the establishment of acquired immunity (5). Thus, initial activation of 
innate mechanisms is essential for TB protection. NK cells mediate early protection 
against M. tuberculosis and a variety of intracellular pathogens (6). NK cells are capable 
of rapidly producing IFN-γ as well as lysing target cells in the absence of prior activa-
tion. The early production of IFN-γ by NK cells at inflammatory sites activates phago-
cytic cells and primes antigen-presenting cells for IL-12 production (7). IL-12 regulates 
human macrophages and shifts the adaptive immune responses towards T helper type 1 
(Th1) mechanisms necessary for elimination of intracellular M. tuberculosis (8,9). It has 
been indicated that NK cell derived IFN-γ differentially regulates T-independent resis-
tance and granulocyte function in AIDS patients or other CD4+ T cell compromised in-
dividuals with M. tuberculosis infection (10). 
Although, the most widely used biomarker correlated with TB protection is the IFN-γ 
secretion, additional biomarkers including those from innate responses may also be 
considered. 
CD16 molecules are involved in cytotoxic activities and are expressed on different cells 
such as NK, NKT, monocytes, macrophages and neutrophils. CD56 or neural cell adhe-
sion molecules are expressed on the surface of neurons, glia, skeletal muscle and natural 
killer cells. They have a role in cell-cell adhesion and in homing into inflammation ar-
eas. Indeed, activated cells are able to migrate to sites of infection via intercellular adhe-
sion molecules such as CD56. On the other hand, CD56 expressing cells have been de-
scribed as a subset of regulatory T cells in response to intracellular pathogens. CD56 
positive lymphocytes are also the major cells in immuno-surveillance and anti tumor 
responses (11,12). An unusual CD56- NK subset that is greatly expanded in HIV-
viremic individuals is phenotypically and functionally examined. These NK cells are 
reported to have association with extremely poor cytotoxic functions and reduced secre-
tion of certain cytokines (13).  
NK cells are phenotypically characterized by CD56+, CD3- and CD16+ molecules. 
Based on the density of CD56 and CD16 (FCγR111) surface markers, two major func-
tional subpopulations of NK cells are identified in humans. Approximately 90% of pe-
ripheral NK cells are low density CD56 (CD56dim) and high density CD16 (CD16bright), 
which are involved in Antibody Dependent Cell Mediated Cytotoxicity (ADCC) re-
sponses. A minor percentage of NK cells expressing high levels of CD56 (CD56bright) 
produce IFN-γ and other cytokines with a low cytotoxic activity (11). CD56bright NK 
cells are abundant in human secondary lymphoid organs and inflammatory sites where 
they may interact with T cells and thereby contribute to the control of the disease activ-
ity (14).  
Since NK cells are the most abundant CD56/CD16 positive cells in peripheral blood 
mononuclear cells, in this study these two markers were employed to determine the 
phenotypic status of NK cells. Due to the involvement of CD56 and CD16 molecules in 
protection against intracellular pathogens, the aim of this study was to investigate the 
phenotypic differences of lymphocytes from MDR-TB and NR-TB patients regarding 
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these two markers. Moreover, based on the reports indicating the implication of other 
leukocytes in TB infection (3,10,11), we compared the percentages of monocytes, neu-
trophils and total lymphocytes from MDR and NR patients and healthy controls. Deter-
mination of lymphocytes and NK subpopulations may be helpful to understand the con-
dition of host immunity. These findings may also be useful to predict drug resistance in 
TB patients. 
 
 
MATERIALS AND METHODS  
 
Participants. Two groups of patients i.e. MDR-TB and NR-TB were selected from the 
Masih Daneshvari hospital according to their clinical and paraclinical findings. Patients 
consisted of 33 tuberculosis patients (aged 18-50 years) with positive bacilloscopy and 
radiological thorax alterations. They had at least one period of TB treatment, two posi-
tive sputum smear tests and a positive sputum culture. MDR-TB subjects (n=13) were 
resistant to isoniazid and rifampin. Twenty TB patients considered in this study were 
drug nonresistant. Forty blood donors aged 20 to 48 years were considered as healthy 
controls. Because of the BCG vaccination in Iran, all healthy blood donors were tuber-
culin reactive (PPD positive skin test). Study was approved by the ethical review board 
of the National Research Institute of Tuberculosis and Lung Disease (NRITLD). All 
subjects in this study showed negative serology test for HIV and gave informed consent 
to enter the study. 
Sample Preparation. 5 ml of peripheral blood was collected in EDTA as anticoagulant. 
Peripheral blood mononuclear cells (PBMC) were isolated by ficoll-hypaque density 
gradient centrifugation. PBMCs were washed once in RPMI 1640 supplemented with 
5% FCS and once in phosphate buffered saline (PBS) plus 1% FCS at 4ºC. Cells were 
then resuspended in ice-cold staining buffer (PBS, 3% FCS) at 5× 106 cells/ml. Cells 
were stained in aliquots of 100 μL with fluorochorome-conjugated monoclonal antibod-
ies for 20 minutes. Anti-human CD16 Ab (VEP13) conjugated with phycoerythrin 
(Miltenyi Biotec, Germany) and monoclonal Ab to human CD56 antigen conjugated 
with fluorescein isothiocyanate (FITC) from Invitrogen (Canada) were applied for cell 
staining according to manufacturers’ instructions. Cells were then washed once by cen-
trifugation at 540 ×g and resuspended in 0.2 M PBS prior to flow cytometry. 
Flow Cytometry. Data acquisition was carried out by a Partec flow cytometer. Lym-
phocytes were gated into the window named R1 on size versus granularity dot plots. 
Information on the 20000 events for each sample was stored. The phenotype of different 
cell subpopulations was determined based on CD56 and CD16 intensity and results 
were expressed as the percentage of cell subsets within the lymphocyte population. A 
flow cytometric pattern from one of the cases and the method for drawing the quadrants 
is illustrated in Figure 1. For each antigenic determinant, the percentage of positive cells 
stained above the negative control values was determined. The proportions of CD56+ 
CD16+, CD56dim CD16+/- and CD56bright CD16+/- subsets were calculated using dot plots. 
As shown in figure 1, different gating was used for calculating the percentages of cell 
subsets according to the density of CD56 and CD16 as follows:  
CD56+ /CD16+ = Q2, CD56- /CD16- = Q3, CD56bright /CD16bright = QC2, CD56- /CD16 
bright = QB4, CD56bright /CD16- = QA4, CD56bright /CD16dim = QA2-QC2, CD56dim 
/CD16bright = QC4-QB4, CD56dim /CD16- = QA3-Q3, CD56dim /CD16dim = QA4- Q4 – 
(CD56dim /CD16bright), CD56- /CD16dim = QC3-QA3-(CD56dim /CD16dim), CD56dim 
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/CD16+/- = (CD56dim /CD16bright) + (CD56dim /CD16dim) + (CD56dim /CD16-), CD56 
bright /CD16+/- = (CD56bright /CD16bright) + (CD56bright /CD16dim) + (CD56 bright /CD16-). 
 
 
Figure 1. A sample of flow cytometric profile of PBMCs. Peripheral blood mononuclear cells 
were stained with CD56-FITC and CD16-PE mAbs. Cells were gated on lymphocytes for each 
experiment. Distinct cell subpopulations for CD56 and CD16 markers are calculated from per-
centages given in different quadrants.  
 
 
Statistical Analysis. For all variables, mean and standard deviations were calculated. 
The statistical significance of the immunophenotypic differences observed between cell 
subsets was established using non-parametric Mann Whitney test. P values less than 
0.05 were considered statistically significant.  
 
 
RESULTS 
 
Leukocytes analysis is shown in Table 1. As seen, the percentages of monocytes were 
elevated in both MDR and NR-TB patients but, neutrophils increased only in NR-TB 
group. Moreover, we found that, lymphocyte percentages from all TB patients de-
pressed significantly in comparison with normal controls (p≤0.05). 
 
Table 1. Differential leukocyte percentages from patients with multidrug- 
resistant and drug non-resistant tuberculosis, and from healthy controls. 
 
 MDR-TB 
    % 
NR-TB 
    % 
Healthy control 
    % 
Neutrophils 59 ±  `8 72 ±  10* 51 ±  7 
Lymphocytes 19 ±  4* 16 ±  2* 34 ±  4 
Monocytes 10 ±  1.9* 7.4 ±  1*   4 ±  1 
*Statistically significant with respect to normal subjects. Data are expressed as mean ± SD of the percentages.  
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Data on CD56 and CD16 molecules obtained from flow cytometer were used to calcu-
late the percentages of whole CD56+ CD16+ and also the proportion of each cell subset 
in gated lymphocyte population. We found that the percentages of CD56+CD16+ cells in 
MDR- and NR-TB patients were significantly lower than those in normal controls 
(p≤0.05). Furthermore, the proportion of CD56brightCD16+ and CD56dimCD16+ cells 
showed significant decreases in both MDR and NR patients in comparison with healthy 
controls. Conversely, CD56brightCD16- and CD56dimCD16- cells showed higher percent-
ages in patient groups compared to those in the healthy control (p≤0.01). Additionally, a 
significant rise was detected in CD56brightCD16- cells of MDR-TB patients in compari-
son with NR-TB (3.0% vs. 0.4%). To highlight the significant differences among the 
results numerically listed in Table 1, the changes are represented in the form of bar 
graphs in Figure 2. Collectively, as demonstrated in Figure 2, we found that in both 
types of TB patients, all the CD56+CD16+ (CD56dim/brightCD16+) subsets were signifi-
cantly lower, and all the CD56+CD16- (CD56dim/brightCD16-) subsets were higher than 
those in normal controls (p≤0.05). Furthermore, the CD56-CD16+ subset showed higher 
percentages in TB patients compared with normal individuals (p≤0.005). 
 
 
DISCUSSION 
 
The mechanism of protective immunity, especially those related to innate responses 
against M. tuberculosis in humans, is not fully understood (3). During TB infection 
dendritic cells and macrophages secret pro-inflammatory cytokines which in turn recruit 
NK, neutrophil and other innate effector cells. Due to the involvement of CD56 and 
CD16 bearing cells in the production of cytokines and cytotoxic activities against TB, 
we have investigated the phenotypic differences of these cells in peripheral blood from 
MDR-TB, DR-TB and healthy controls (15). First, we found that all subsets of CD56+ 
CD16+ cells from TB patients had lower percentages compared to normal controls (Fig-
ure 2a). As the majority of NK cells in peripheral blood express CD56 and CD16 mole-
cules, the suppression shown in CD56+CD16+ subsets could be attributed to NK cells. 
However, since we did not use the triple staining of PBMCs, CD3 positive cells were 
not excluded from CD56+CD16+ populations. Therefore, activated CD16 NKT, the 
other effector cells in TB may be included in CD56+CD16+ subsets. Thus, a decrease in 
CD16 positive cells is likely to indicate the suppression of cytotoxic activities of NK 
and NKT cells against TB infection. According to Yildiz (16), MDR-TB may result 
from either insufficiency of host cellular immune response or Mycobacterial mecha-
nisms. Confirming the role of CD16 expressing cells, we found a significant decline in 
CD56dim/brightCD16+ in addition to the expansion of CD56dim/brightCD16- lymphocytes in 
peripheral blood of TB patients in both MDR and NR-TB (Figures 2c, 2e, 2d and 2f). 
Interestingly, in the case of CD56brightCD16- lymphocytes, MDR-TB patients showed 
higher percentages than NR patients (Figure 2f). Indeed, increase of all CD56+CD16- 
subsets in peripheral blood of TB patients could confirm the lower cytotoxic activity, 
especially in MDR tuberculosis. Similar findings have been previously reported in TB 
and other diseases by other investigators (17-19). 
Schierloh and colleagues reported that increased susceptibility to apoptosis of 
CD56dimCD16+ NK cells induces the enrichment of IFN-γ producing CD56bright cells 
(19). 
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Figure 2. Peripheral blood mononuclear cells from 13 multidrug resistant tuberculosis (MDR-
TB), 20 drug nonresistant (NR-TB) and 40 healthy subjects were stained with CD56-FITC and 
CD16-PE mAbs. Lymphocyte subsets were then determined by flow cytometry. Here, the re-
sults from those subsets with statistically significant differences (p≤0.05) are illustrated. 
 
 
Accordingly, we found the suppression of CD56dimCD16+ and the expansion of 
CD56brightCD16- cells especially in MDR patients. Hence, we suggest that higher per-
centage of CD56brightCD16- subsets in peripheral blood of MDR-TB may be due to the 
less migration of these cells into the infection sites and to low local IFN-γ secretion. 
These findings could be considered as mechanisms involved in the onset of drug resis-
tance in tuberculosis.  
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It is known that IFN-γ is a key mediator in providing protective immunity to M. tuber-
culosis, thus recombinant IFN-γ has been reported to activate human alveolar macro-
phages in vivo (20). Since the main route of entry of this organism is the respiratory 
system, alveolar macrophages are important cell types which combat this pathogen (21). 
Thus, we suggest that less migration of CD56bright cells into the lung of MDR-TB pa-
tients leads to a decrease in local IFN-γ and the suppression of anti tuberculosis immu-
nity. Accordingly, Grahmann et al. have recently introduced a new protocol for IFN-γ 
therapy in MDR-TB patients (20). 
It has been known that signalling via CD16 (FC-γR111) results in the production of cy-
tokines and several chemokines, and causes degranulation of NK and NKT cells (5). 
Although the cytotoxic activity was not measured in our study, the reduction of CD16 
subsets shown in this study is consistent with the work of others who reported decreases 
of NK cell activities in tuberculosis (22). Consequently, we conclude that TB patients 
may have a failure in whole cytotoxic activities of CD56+ lymphocytes.  
It has been previously described that CD56-CD16+ NK cells are functionally and pheno-
typically immature, but capable of maturation towards CD56+CD16+ cells (9). The ele-
vation of this subpopulation in TB patients observed in our study (Figure 2b) is in 
agreement with this finding and also with a report by Veenstra et al. (18). In another 
study, the expansion of this NK subset from myasthenia gravis patients has been attrib-
uted to the deleterious NK cell functioning (23). However, we suggest that the differ-
ences of lymphocyte subpopulations in TB patients are likely secondary to TB infection. 
But, those changes which are specifically seen in MDR patients may be attributed to 
other reasons. 
Considering previous reports on leukocytes which indicated an increase of granulocytes 
and granulocyte/lymphocyte ratios in TB patients (24), we compared these cells in our 
study groups. It is known that monocytes would play a regulatory role in the NK cell 
activity not only by the cytokines, but also through a signalling process mediated by co-
stimulatory molecules (9). According to previous studies monocytes from TB patients 
regulate the NK function through an indirect mechanism leading to down regulation of 
costimulatory/adhesion molecules and/or IFN-γ production (6). In this study, we ob-
served a significant elevation of monocytes especially in MDR-TB patients which may 
cause a decrease in IFN-γ production by NK cells. Moreover, it has been reported that 
neutrophils can mediate antimicrobial activity against M. tuberculosis by delivering an-
timicrobial peptides to macrophages. Indeed, macrophages have been reported to ac-
quire neutrophil granules for antimicrobial activity against intracellular pathogens (25). 
Accordingly, we found a significant reduction in neutrophils from MDR-TB patients but 
not from NR-TB ones compared to healthy subjects. In addition, total blood lympho-
cytes were suppressed in both MDR and NR-TB patients. We conclude that these 
changes in leukocytes may cause the adaptive immune response insufficient especially 
in MDR-TB patients. Taken together, the characteristic patterns in CD56/CD16 subsets 
and leukocyte changes seen in MDR-TB patients may be considered as an additional 
cause of disease severity and high mortalities in this group of patients. However, further 
specific studies on CD56 lymphocyte subsets and their function using expanded sample 
sizes are recommended to confirm these suggestions. 
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